The FDA has accepted the resubmission of the BLA of Ordspono for review in relapsed/refractory follicular lymphoma following previous systemic therapy.
Survey finds a strong need for data unification, multi-cloud adoption, AI-driven transformation, and metadata control as organizations seek to maximi ...
Bailard Inc. increased its stake in Regeneron Pharmaceuticals by 10.1% in Q4, raising its holdings to 13,422 shares.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback